Alisha Samnani
Medical · Dallas, TXNPI 1891484747
Payments from drug & device makers
Across 82 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$432
- AstraZeneca$196
- Pfizer$141
- Lilly USA, LLC$138
- Sanofi-aventis U.S. LLC$135
- Sumitomo Pharma America, Inc.$92
- plus $627 from 15 others
What the payments were for
- Food & beverage$1,761100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $432 |
| AstraZeneca | 6 | $196 |
| Pfizer | 6 | $141 |
| Lilly USA, LLC | 2 | $138 |
| Sanofi-aventis U.S. LLC | 5 | $135 |
| Sumitomo Pharma America, Inc. | 4 | $92 |
| Astellas Pharma US Inc | 5 | $76 |
| Exact Sciences | 3 | $71 |
| Johnson & Johnson | 3 | $66 |
| Averitas Pharma Inc. | 2 | $55 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Boston Scientific | 1 | $43 |
| Vertex | 2 | $41 |
| Sanofi Pasteur Inc. | 1 | $37 |
| Merck | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Amgen | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Boehringer Ingelheim | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $19 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,761 in reported general payments places this provider in the 65th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 68 | $1,149 |
| Celecoxib | 23 | $1,038 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $1,016 |
| Atorvastatin Calcium | 31 | $412 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 19 | $319 |
| Methylprednisolone | 42 | $318 |
| Azelastine Hcl | 13 | $271 |
| Diclofenac Sodium | 11 | $267 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $205 |
| Pantoprazole Sodium | 23 | $193 |
| Lisinopril | 20 | $189 |
| Losartan Potassium | 14 | $174 |
| Amlodipine Besylate | 23 | $144 |
| Doxycycline Monohydrate | 13 | $142 |
| Methocarbamol | 24 | $142 |
Paid to pharmacies, not to this prescriber.
Other medical in Dallas
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
- Andrew GarzaDallas$43K
- Alyssa SpiegelDallas$18K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.